ArticleThe Journal of infectious diseases2025
Long-term Kinetics of Vibriocidal Antibody Responses After Vibrio cholerae Infection in the Democratic Republic of Congo.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Statistical Modelling of Waning Immunity After Shanchol™ Vaccination: A Prospective Cohort Study.Vaccines · 2026Article
- Cholera in North Kivu: impacts of armed conflict on the resurgence of the epidemic, a narrative review.Annals of medicine and surgery (2012) · 2025Review
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
Interpretation of seroepidemiology studies of cholera relies on knowledge of antibody kinetics, which are not well known in African populations. We performed vibriocidal antibody assays on 212 serum samples from 115 patients with culture-positive cholera (median age, 8 years) in Goma, Democratic Republic of Congo, which were collected at enrollment and 3 to 449 days after. Vibriocidal responses peaked at 7 to 40 days after symptom onset, with 89.5% waning to a titer ≤160 by 180 days. We used a bayesian exponential decay model to show an 88% probability of the posterior distribution supporting a faster decay in children ≤5 years of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.